The Journal of Immunology, Vol 144, Issue 1 209-213, Copyright © 1990 by American Association of Immunologists

ARTICLES

Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol

NV Katre
Cetus Corporation, Emeryville, CA 94608.

Human rIL-2, expressed and purified from Escherichia coli, is currently being tested as an anticancer therapeutic agent. Some of the patients undergoing clinical trials with rIL-2 have developed antibodies to rIL- 2. We describe a chemical modification of rIL-2 that reduces its immunogenicity. rIL-2 has been chemically modified with a water soluble polymer, monomethoxy polyethylene glycol (PEG). This covalent conjugate PEG-rIL-2 has enhanced solubility and extended in vivo circulation. Attachment of PEG to rIL-2 reduces its immunogenicity when tested in rabbits and in mice. Ag-specific IgG antibody titers were 100 to 1000- fold lower when PEG-rIL-2 was used as the Ag, compared to rIL-2. In a long term study, 7 of 10 rabbits injected with PEG-rIL-2 had no Ag- specific IgG antibody response. In these seven rabbits, the in vivo behavior of the injected PEG-rIL-2 remained essentially unchanged after repeated immunizations. PEG-rIL-2 injected before rIL-2 injections, immunosuppressed the antibody response to rIL-2 in rabbits. The maintenance of the systemic exposure of PEG-rIL-2 after repetitive dosing is related to its decreased immunogenicity. Thus, the PEGylation (covalent attachment of PEG) of rIL-2-enhances its potential as an anticancer therapeutic.

This article has been cited by other articles:

				T. Ebensen, C. Link, P. Riese, K. Schulze, M. Morr, and C. A. Guzman A Pegylated Derivative of {alpha}-Galactosylceramide Exhibits Improved Biological Properties J. Immunol., August 15, 2007; 179(4): 2065 - 2073. [Abstract] [Full Text] [PDF]

				R. L. Basser, E. O'Flaherty, M. Green, M. Edmonds, J. Nichol, D. M. Menchaca, B. Cohen, and C. G. Begley Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor Blood, April 1, 2002; 99(7): 2599 - 2602. [Abstract] [Full Text] [PDF]

				M. R. Hamblin, J. L. Miller, I. Rizvi, B. Ortel, E. V. Maytin, and T. Hasan Pegylation of a Chlorine6 Polymer Conjugate Increases Tumor Targeting of Photosensitizer Cancer Res., October 1, 2001; 61(19): 7155 - 7162. [Abstract] [Full Text] [PDF]

				T. Hauet, D. Mothes, J.-M. Goujon, M. Carretier, and M. Eugene Protective Effect of Polyethylene Glycol against Prolonged Cold Ischemia and Reperfusion Injury: Study in the Isolated Perfused Rat Kidney J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 946 - 952. [Abstract] [Full Text]

				A. J. Sytkowski, E. D. Lunn, K. L. Davis, L. Feldman, and S. Siekman Human erythropoietin dimers with markedly enhanced in vivo activity PNAS, February 3, 1998; 95(3): 1184 - 1188. [Abstract] [Full Text] [PDF]

				D. K. Pettit, T. P. Bonnert, J. Eisenman, S. Srinivasan, R. Paxton, C. Beers, D. Lynch, B. Miller, J. Yost, K. H. Grabstein, et al. Structure-Function Studies of Interleukin 15using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling J. Biol. Chem., January 24, 1997; 272(4): 2312 - 2318. [Abstract] [Full Text] [PDF]

				G. Hooftman, S. Herman, and E. Schacht Review: Poly(Ethylene Glycol)s with Reactive Endgroups. II. Practical Consideration for the Preparation of Protein-PEG Conjugates Journal of Bioactive and Compatible Polymers, April 1, 1996; 11(2): 135 - 159.

				C. Cunningham-Rundles, K. Kazbay, J. Hassett, Z. Zhou, and L. Mayer Enhanced Humoral Immunity in Common Variable Immunodeficiency after Long-Term Treatment with Polyethylene Glycol-Conjugated Interleukin-2 N. Engl. J. Med., October 6, 1994; 331(14): 918 - 921. [Full Text]